{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:56:47Z","timestamp":1770814607209,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2002,3]]},"DOI":"10.4065\/77.3.262","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:19:36Z","timestamp":1232759976000},"page":"262-270","source":"Crossref","is-referenced-by-count":80,"title":["Upper Gastrointestinal Tract Safety of Risedronate: A Pooled Analysis of 9 Clinical Trials"],"prefix":"10.4065","volume":"77","author":[{"given":"Hugh","family":"Taggart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Bolognese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark P.","family":"Ettinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G.","family":"Josse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Zippel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvano","family":"Adami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa F.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen P.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/77.3.262_bib1","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0011-393X(97)80101-4","article-title":"Bisphosphonates in the treatment of osteoporosis in 1997: a review","volume":"58","author":"Francis","year":"1997","journal-title":"Curr Ther Res"},{"key":"10.4065\/77.3.262_bib2","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/0011-393X(95)85087-2","article-title":"Oral bisphosphonates in the treatment of osteoporosis: a review","volume":"56","author":"Francis","year":"1995","journal-title":"Curr Ther Res"},{"key":"10.4065\/77.3.262_bib3","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.4065\/77.3.262_bib4","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.4065\/77.3.262_bib5","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.4065\/77.3.262_bib6","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial","volume":"15","author":"Reid","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.4065\/77.3.262_bib7","first-page":"704","article-title":"A new probable increasing cause of esophageal ulceration: alendronate","volume":"92","author":"Colina","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.4065\/77.3.262_bib8","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"de Groen","year":"1996","journal-title":"N Engl J Med"},{"key":"10.4065\/77.3.262_bib9","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1001\/jama.1996.03530440012012","article-title":"Important information regarding alendronate adverse reactions","volume":"275","author":"Nightingale","year":"1996","journal-title":"JAMA"},{"key":"10.4065\/77.3.262_bib10","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/bmj.315.7117.1235a","article-title":"Incidence of gastrointestinal side effects due to alendronate is high in clinical practice [letter]","volume":"315","author":"Kelly","year":"1997","journal-title":"BMJ"},{"key":"10.4065\/77.3.262_bib11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.18553\/jmcp.1998.4.5.488","article-title":"Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation","volume":"4","author":"Ettinger","year":"1998","journal-title":"J Manag Care Pharm"},{"key":"10.4065\/77.3.262_bib12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1053\/gast.2000.16517","article-title":"Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women","volume":"119","author":"Lanza","year":"2000","journal-title":"Gastroenterology"},{"key":"10.4065\/77.3.262_bib13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1023\/A:1018849415297","article-title":"Nonclinical model for assessing gastric effects of bisphosphonates","volume":"42","author":"Blank","year":"1997","journal-title":"Dig Dis Sci"},{"key":"10.4065\/77.3.262_bib14","first-page":"1390","article-title":"Figures given in letter were prevalences, not incidences [reply]","volume":"316","author":"Taggart","year":"1998","journal-title":"BMJ"},{"issue":"suppl 1","key":"10.4065\/77.3.262_bib15","first-page":"S69","article-title":"Risedronate prevents bone loss in early postmenopausal women [abstract]","volume":"64","author":"Hooper","year":"1999","journal-title":"Calcif Tissue Int"},{"key":"10.4065\/77.3.262_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.4065\/77.3.262_bib17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.4065\/77.3.262_bib18","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1210\/jc.85.5.1895","article-title":"Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial","volume":"85","author":"Fogelman","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 3","key":"10.4065\/77.3.262_bib19","first-page":"111","article-title":"Risedronate increases bone mineral density at the hip, spine and radius in postmenopausal women with low bone mass [abstract]","volume":"8","author":"McClung","year":"1998","journal-title":"Osteoporos Int"},{"key":"10.4065\/77.3.262_bib20","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/bmj.295.6609.1301","article-title":"Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD)","volume":"295","author":"Harinck","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.4065\/77.3.262_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0169-6009(89)90095-0","article-title":"Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD","volume":"5","author":"Valkema","year":"1989","journal-title":"Bone Miner"},{"key":"10.4065\/77.3.262_bib22","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.288.6420.828-a","article-title":"Side effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone diseases","volume":"288","author":"Mautalen","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.4065\/77.3.262_bib23","first-page":"1377","article-title":"Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis","volume":"4","author":"Ettinger","year":"1998","journal-title":"Am J Manag Care"},{"key":"10.4065\/77.3.262_bib24","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0002-9343(97)00242-8","article-title":"Upper gastrointestinal adverse events and cyclical etidronate","volume":"103","author":"van Staa","year":"1997","journal-title":"Am J Med"},{"key":"10.4065\/77.3.262_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/8756-3282(95)00436-X","article-title":"Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis [published correction appears in Bone. 1996;19:78]","volume":"18","author":"Devogelaer","year":"1996","journal-title":"Bone"},{"key":"10.4065\/77.3.262_bib26","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.4065\/77.3.262_bib27","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0002-9343(96)00282-3","article-title":"Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis","volume":"101","author":"Tucci","year":"1996","journal-title":"Am J Med"},{"issue":"suppl 1","key":"10.4065\/77.3.262_bib28","first-page":"S525","article-title":"Update of alendronate safety in clinical trials [abstract]","volume":"14","author":"Leung","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.4065\/77.3.262_bib29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archinte.160.4.517","article-title":"Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial","volume":"160","author":"Bauer","year":"2000","journal-title":"Arch Intern Med"},{"issue":"suppl 3","key":"10.4065\/77.3.262_bib30","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1007\/BF01623005","article-title":"Design of the Fracture Intervention Trial","volume":"3","author":"Black","year":"1993","journal-title":"Osteoporos Int"},{"key":"10.4065\/77.3.262_bib31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/archinte.161.1.107","article-title":"Alendronate and naproxen are synergistic for development of gastric ulcers","volume":"161","author":"Graham","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.4065\/77.3.262_bib32","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/archinte.160.11.1702","article-title":"Alendronate and nonsteroidal anti-inflammatory drug interaction safety is not established [letter]","volume":"160","author":"Rothschild","year":"2000","journal-title":"Arch Intern Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611623586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611623586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T13:56:31Z","timestamp":1633010191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611623586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["S0025619611623586"],"URL":"https:\/\/doi.org\/10.4065\/77.3.262","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}